Home › Funds › 683 Capital Management, LLC › MDGL

683 Capital Management, LLC position in MDGL

MADRIGAL PHARMACEUTICALS INC · Health Care

683 Capital Management, LLC reported holding 90,000 shares of MDGL (MADRIGAL PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$45.4M, representing 2.01% of its reported portfolio and ranking #9 among its reported holdings. 683 Capital Management, LLC has disclosed MDGL holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)90.00K sh
Reported value held$45.36M
Portfolio Weight2.01%
First reportedQ3 2023
Last changeHold
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How 683 Capital Management, LLC's MDGL position evolved

683 Capital Management, LLC first disclosed a stake in MDGL in Q3 2023 at 10,000 shares (US$1.5M). The position peaked in Q3 2025 at 152,000 shares, worth US$69.7M. Across 13 filings, 683 Capital Management, LLC increased the stake 4 time(s), trimmed it 4 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 90,000 shares valued at US$45.4M. Notable position changes include a 1679% increase in Q1 2024 (shares rose 5% over the following quarter), a 2258% increase in Q1 2025 (shares fell 9% over the following quarter), a 511% increase in Q3 2025 (shares rose 27% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 10.00K $1.46M New
Q4 2023 10.00K $2.31M Hold
Q1 2024 177.90K $47.51M Add
Q2 2024 11.50K $3.22M Reduce
Q3 2024 11.50K $2.44M Hold
Q4 2024 1.00K $308.57K Reduce
Q1 2025 23.58K $7.81M Add
Q2 2025 24.86K $7.53M Add
Q3 2025 152.00K $69.72M Add
Q4 2025 99.00K $57.65M Reduce
Q1 2026 90.00K $47.11M Reduce
Q2 2026 90.00K $48.33M Hold
Q3 2026 90.00K $45.36M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About MDGL and 13F data

MDGL (MADRIGAL PHARMACEUTICALS INC) is a Health Care company. 46 other funds we track also report a position in MDGL — the largest reported positions include BAKER BROS. ADVISORS LP (US$1.15B), Janus Henderson Group (US$1.05B), Jupiter Topco LLC (US$1.04B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding MDGL

All MDGL fund holders →

FAQ

How long has 683 Capital Management, LLC held MDGL?

683 Capital Management, LLC has disclosed MDGL holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is 683 Capital Management, LLC's current position in MDGL?

As of Q3 2026, 683 Capital Management, LLC holds 90.00K shares of MDGL (MADRIGAL PHARMACEUTICALS INC), valued at $45.36M, representing 2.01% of its reported portfolio and ranking #9.

Has 683 Capital Management, LLC been buying or selling MDGL?

In the latest 13F filing (Q3 2026), 683 Capital Management, LLC held unchanged its position in MDGL. The position peaked in Q3 2025 at 152.00K shares.

Which other funds hold MDGL?

Other major institutional holders of MDGL include BAKER BROS. ADVISORS LP, Janus Henderson Group, Jupiter Topco LLC, among 46 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.